Recommended

Lilly demonstrates alopecia areata promise in major study
Novartis bets $12bn on potential first-in-class RNA therapeutics
Process analytical tool could aid real-time monitoring in vaccine manufacturing
CPHI Pharma Awards 2025 winners announced
Drug delivery study offers potential “paradigm shift” in restenosis
Lilly AI supercomputer set to advance pharma manufacturing
FDA draft guidance to streamline biosimilar development
Novo Nordisk bids $6.5 billion for Metsera
news

Orally disintegrating tablets market driven by CNS disease treatments

0
SHARES

The preference for orally disintegrating tablets (ODT) to treat CNS-related diseases will increase the market from $12bn in 2018, with a solid growth rate.

The global orally disintegrating tablets (ODTs) market was valued at nearly $12 billion in 2018 and will exhibit a solid compound annual growth rate (CAGR) during the forecast period 2019-2029, a new report has said.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

This is due to the growing preference for using ODTs to treat diseases related to the central nervous system (CNS), gastrointestinal (GI), cardiovascular disorders and allergies, explained the report by Persistence Market Research.

Global subcutaneous drug delivery devices market expected to grow

CNS diseases remain the primary area of application for ODTs, the report said, with researchers and healthcare providers increasingly focusing on medical conditions such as encephalitis, autism, Alzheimer’s disease, schizophrenia, depressive disorders and others to increase the application of ODTs.

The easy disintegration of ODTs in saliva within a few seconds and the accuracy of dose as compared to liquid forms and chewable tablets are also expected to increase the adoption of ODTs in diseases such as ulcers of the throat, the report continued.

Furthermore, due to consumers facing swallowing problems, the bitter taste of drugs and patient in-compliance, manufacturers are reportedly focusing to improve drug formulations to help them gain an edge in terms of innovation, which further aids in the growth of this market.

Share via
Share via